secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041404
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Q2 2023: cash $358M, revenue $10.4M, initiates pivotal luvelta trial, Blackstone deal
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $358.3M; Vaxcyte shares valued at $33.3M; runway into H1 2025.
- Revenue $10.4M (down from $28.1M YoY); total operating expenses $56.6M (up from $47.5M).
- Initiated REFRaME Phase 2/3 pivotal study for luvelta in platinum-resistant ovarian cancer; enrollment underway.
- Received $140M upfront from Blackstone royalty monetization; eligible for up to $250M milestone payments.
- Luvelta endometrial cancer data to be presented at ESMO 2023; updated ovarian data expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023041404/0000950170-23-041404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023041404/stro-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer